stockrowRecursion Pharmaceuticals, Inc. (RXRX) vs Vericel Corporation (VCEL)
- Recursion Pharmaceuticals, Inc. RXRX 3.57 +2.00%
- Vericel Corporation VCEL 54.08 +4.44%
Recursion Pharmaceuticals, Inc. and Vericel Corporation are both Biotechnology companies. Vericel Corporation is the larger, with a market value of $2.7B against $2.2B — 1.2× the size. Recursion Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Vericel Corporation trades at 77.8×. Recursion Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 56.2% against 25.3%. Vericel Corporation has the higher net margin (10.3% vs −697.1%) and the higher return on invested capital (7.88% vs −88.5%). Across the 19 metrics below, Vericel Corporation leads on 16 and Recursion Pharmaceuticals, Inc. on 3.
Valuation
Profitability
| Metric | RXRX | VCEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 29.21% | 74.47% | 65.16% |
| Operating margin | (725.44%) | 8.32% | 0.00% |
| Net margin | (697.13%) | 10.27% | 0.00% |
| Free cash flow margin | (460.89%) | 17.86% | 0.00% |
| Return on equity | (48.72%) | 9.44% | (50.12%) |
| Return on assets | (36.29%) | 6.86% | (45.60%) |
| Return on invested capital | (88.54%) | 7.88% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack